Quarterly report pursuant to sections 13 or 15(d)

7. SUBSEQUENT EVENTS

v2.4.0.6
7. SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
NOTE 7 - SUBSEQUENT EVENTS

The Company has evaluated events and transactions that occurred from March 31, 2013 through the date of filing, for possible disclosure and recognition in the financial statements. Except as discussed below, the Company did not have any material subsequent events that impact its financial statements or disclosures.

 

In April 2013, the Company approved a grant of stock options to a Consultant under the 2011 Plan for the purchase of 7,500 shares of the Company’s common stock at an exercise price of $1.00 per share as part of the Consultants compensation for each month of service.

 

In April 2013, the Company approved a grant of warrants and restricted shares to a corporate communications and investor relations Consultant and service provider as partial consideration for her services to the Company: (a) a five-year warrant to purchase 100,000 shares of the Corporation’s common stock at a strike price of $1.00 per share, and (b) 12,000 shares of the Corporation’s common stock per month of service.

 

In April 2013, the Company approved a grant to a Consultant of 48,000 shares of the Company’s common stock for services to be delivered over a period of up to six months  in connection with the identification and engagement of a pharma partner or partners for the Company’s products.